Literature DB >> 3838779

Continuous epidural narcotic analgesia for intractable pain due to malignancy.

T Yablonski-Peretz, B Klin, Y Beilin, E Warner, S Baron, D Olshwang, R Catane.   

Abstract

Eighty consecutive cancer patients with severe pain, uncontrolled by conventional narcotic analgesics, received a 2-mg test dose of morphine epidurally. Thirty-four of them had significant pain relief and were thus selected to receive continuous treatment. This consisted of 2-6 mg of morphine administered every 8-24 hours through an indwelling epidural catheter. The duration of treatment was from 1 to 28 weeks with a median of 4 weeks. Twenty-five (76%) of the patients experienced complete relief of pain, while nine had only a partial analgesic response. Complications were minimal. No sepsis, hypotension, or respiratory depression occurred. It is recommended that cancer patients with intractable pain will be selected for continuous epidural analgesia by evaluating their response to a test dose of epidural morphine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3838779     DOI: 10.1002/jso.2930290104

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  2 in total

1.  Epidural buprenorphine or morphine for the relief of head and neck cancer pain.

Authors:  Y Hashimoto; T Utsumi; H Tanioka; B M Rigor
Journal:  Anesth Prog       Date:  1991 Mar-Apr

2.  The Infusaid pump in the management of intractable cancer pain.

Authors:  D D Bryant; R L DeWitty; G C Dennis
Journal:  J Natl Med Assoc       Date:  1987-03       Impact factor: 1.798

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.